107 results
Page 2 of 6
8-K
EX-99.1
os8s9 85z60v
8 Jun 22
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
cd7fetbknc ll
5 Jan 22
Regulation FD Disclosure
7:38am
8-K
EX-99.1
d5grvj2lt1g d48geuw
30 Dec 21
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022
7:05am
8-K
EX-10.1
kb3m6o0 hbizpvh
15 Sep 21
Immunovant Appoints Renee Barnett as Chief Financial Officer
7:23am
8-K
EX-99.1
0olt7gd0wt1itz
9 Aug 21
Company Ended the Quarter With Cash of Approximately $379 Million
6:56am
PRE 14A
45ayx 3kru
2 Aug 21
Preliminary proxy
4:31pm
8-K
EX-10.1
lnanu
2 Aug 21
Immunovant Receives $200 Million Strategic Investment from Roivant Sciences
8:09am
8-K
EX-10.1
qcv59xz
13 Jul 21
Departure of Directors or Certain Officers
5:14pm
8-K
EX-99.1
gdes 7xourvq
1 Jun 21
Results of Operations and Financial Condition
7:36am